183 related articles for article (PubMed ID: 2376048)
21. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy.
Pak AS; Ip G; Wright MA; Young MR
Cancer Res; 1995 Feb; 55(4):885-90. PubMed ID: 7850804
[TBL] [Abstract][Full Text] [Related]
22. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
23. Active specific adjuvant immunotherapy with vaccinia melanoma oncolysate.
Scoggin SD; Sivanandham M; Sperry RG; Wallack MK
Ann Plast Surg; 1992 Jan; 28(1):108-9. PubMed ID: 1642396
[TBL] [Abstract][Full Text] [Related]
24. Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infiltrating lymphocytes.
Rosenberg SA; Schwarz SL; Spiess PJ
J Natl Cancer Inst; 1988 Nov; 80(17):1393-7. PubMed ID: 3262772
[TBL] [Abstract][Full Text] [Related]
25. Antitumor effect of combination of murine recombinant interferon beta, murine recombinant interferon gamma and human recombinant interleukin-2 in MethA-bearing mice.
Itoh T; Sakata Y; Yoshida Y; Tsushima K; Suzuki H; Saitoh S; Tamura Y; Ogasawara H; Sugimoto N; Takemori H
Cancer Immunol Immunother; 1990; 32(2):88-94. PubMed ID: 2126986
[TBL] [Abstract][Full Text] [Related]
26. Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.
Hornung RL; Back TC; Zaharko DS; Urba WJ; Longo DL; Wiltrout RH
J Immunol; 1988 Nov; 141(10):3671-9. PubMed ID: 2460546
[TBL] [Abstract][Full Text] [Related]
27. In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors.
Iigo M; Sakurai M; Tamura T; Saijo N; Hoshi A
Cancer Res; 1988 Jan; 48(2):260-4. PubMed ID: 2446744
[TBL] [Abstract][Full Text] [Related]
28. Combination of interleukin 12 and interferon alpha gene therapy induces a synergistic antitumor response against colon and renal cell carcinoma.
Mendiratta SK; Quezada A; Matar M; Thull NM; Bishop JS; Nordstrom JL; Pericle F
Hum Gene Ther; 2000 Sep; 11(13):1851-62. PubMed ID: 10986558
[TBL] [Abstract][Full Text] [Related]
29. Interleukin 21 treatment in a murine model as a novel potential cytokine immunotherapy for colon cancer.
Chen C; Liu X; Ren Y
Adv Clin Exp Med; 2018 May; 27(5):583-589. PubMed ID: 29616746
[TBL] [Abstract][Full Text] [Related]
30. Changes in lymphocyte subsets following multiple administration of recombinant interleukin-2 plus recombinant interferon-beta or -gamma in tumor-bearing mice.
Iigo M; Nishikata K; Nakajima Y; Moriyama M
Jpn J Cancer Res; 1989 Jun; 80(6):554-61. PubMed ID: 2527216
[TBL] [Abstract][Full Text] [Related]
31. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma.
Wigginton JM; Komschlies KL; Back TC; Franco JL; Brunda MJ; Wiltrout RH
J Natl Cancer Inst; 1996 Jan; 88(1):38-43. PubMed ID: 8847724
[TBL] [Abstract][Full Text] [Related]
32. Eradication of hepatic metastases of carcinoma H-59 by combination chemoimmunotherapy with liposomal muramyl tripeptide, 5-fluorouracil, and leucovorin.
Asao T; Shibata HR; Batist G; Brodt P
Cancer Res; 1992 Nov; 52(22):6254-7. PubMed ID: 1423270
[TBL] [Abstract][Full Text] [Related]
33. Application of an interleukin 2 slow delivery system to the immunotherapy of established murine colon 26 adenocarcinoma liver metastases.
Fujiwara T; Sakagami K; Matsuoka J; Shiozaki S; Uchida S; Fujioka K; Takada Y; Onoda T; Orita K
Cancer Res; 1990 Nov; 50(21):7003-7. PubMed ID: 2208166
[TBL] [Abstract][Full Text] [Related]
34. Enhanced survival of IFN-alpha augmented IL-2 therapy of pulmonary metastases: efficacy comparable to interleukin-2 and lymphokine activated killer cells.
Kim B; Warnaka P
J Surg Res; 1991 Jan; 50(1):40-6. PubMed ID: 1987429
[TBL] [Abstract][Full Text] [Related]
35. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.
Daftarian P; Song GY; Ali S; Faynsod M; Longmate J; Diamond DJ; Ellenhorn JD
Cancer Res; 2004 Aug; 64(15):5407-14. PubMed ID: 15289349
[TBL] [Abstract][Full Text] [Related]
36. Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long- term remission of liver metastases in a mouse model.
Martinet O; Ermekova V; Qiao JQ; Sauter B; Mandeli J; Chen L; Chen SH
J Natl Cancer Inst; 2000 Jun; 92(11):931-6. PubMed ID: 10841829
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy of liver metastases of human gastric carcinoma with interleukin 2-activated natural killer cells.
Yasumura S; Lin WC; Hirabayashi H; Vujanovic NL; Herberman RB; Whiteside TL
Cancer Res; 1994 Jul; 54(14):3808-16. PubMed ID: 8033100
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy in liver tumours: I. Combined administration of recombinant interleukin-2 (IL-2) and interferon-alpha through the subcutaneous transposed spleen prolongs the half-life of IL-2 in vivo and enhances antitumor effects.
Liu DL; Seifert J; Cwikiel W
Cancer Lett; 1994 Sep; 85(1):31-7. PubMed ID: 7923099
[TBL] [Abstract][Full Text] [Related]
39. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
40. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.
Hill HC; Conway TF; Sabel MS; Jong YS; Mathiowitz E; Bankert RB; Egilmez NK
Cancer Res; 2002 Dec; 62(24):7254-63. PubMed ID: 12499267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
